Skip to main content

Investor Relations

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies.

 
Investor Presentation
Recent News
May 29, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming...

May 28, 2024

Over 18-years at leading life sciences and strategy consulting companies, including Revolution Medicines, Guardant Health, Onyx Pharmaceuticals, and McKinsey & Company SOUTH SAN FRANCISCO, Calif.,...

May 23, 2024

In the news release, IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma, issued

All Releases

Events
Wednesday, June 5, 2024
9:00am EDT

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology

Monday, June 10, 2024
8:00am - 9:00am EDT

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Corinne (Jenkins) Johnson, Vice President, Equity Research, Biotechnology

All Events

Stock Info
NASDAQIDYA

Stock Information

Investor Contact

Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
650-443-6214
investor@ideayabio.com

Subscribe to email alerts
* Required Fields
WE ARE DEDICATED TO

Improving Lives Through Transformative Precision Medicines

Close Menu